Core Viewpoint - The report outlines a reduction in the shareholding of Heilongjiang Chuangda Group Co., Ltd. in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. due to the conversion of exchangeable bonds, resulting in a decrease in ownership from 60.85% to 59.87% [19][21]. Group 1: Shareholding Changes - The shareholding of Heilongjiang Chuangda Group decreased by 0.98% due to the conversion of 9,223,963 shares from the exchangeable bonds "23 Chuang 01 EB" and "23 Chuang 02 EB" [5][21]. - As of the report date, Heilongjiang Chuangda Group holds 563,334,314 shares, representing 59.87% of the total share capital of the company [19][21]. - The total shares converted from both exchangeable bonds amount to 16,550,986 shares, accounting for 1.76% of the total share capital [21]. Group 2: Future Plans and Compliance - Heilongjiang Chuangda Group has no plans to increase or decrease its shareholding in the next 12 months, aside from the ongoing conversion of the exchangeable bonds [4][21]. - The report confirms that the shareholding change does not trigger a mandatory tender offer and will not alter the status of the controlling shareholder or actual controller [19][22]. - The company has complied with all relevant laws and regulations regarding the disclosure of this shareholding change [22].

Group 1 - The core point of the announcement is that the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., has experienced a change in equity that touches the 1% threshold due to the conversion of exchangeable bonds and the repurchase of restricted shares by the company [1][2]. - As of August 1, 2025, Heilongjiang Chuangda Group's shareholding in the company decreased from 61.56% to 60.85%, following the conversion of 7,327,023 shares during the exchange period from November 8, 2023, to August 1, 2025 [1][2]. - The equity change does not result in a change of the controlling shareholder or actual controller of the company, nor does it trigger a mandatory tender offer [2][3]. Group 2 - The exchangeable bonds issued by Chuangda Group are currently in the conversion period, and the decision of bondholders to convert their bonds into shares is uncertain [4]. - The company will fulfill its information disclosure obligations in accordance with laws and regulations if any further equity changes occur [4].

Core Viewpoint - The announcement details a change in the equity stake of the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., indicating a decrease in ownership percentage from 61.56% to 60.85% due to the repurchase and cancellation of restricted shares [1][2]. Group 1 - The controlling shareholder's equity stake decreased from 61.56% to 60.85% [1][2]. - The change in equity does not trigger mandatory tender offer obligations [1]. - The equity change is attributed to the repurchase and cancellation of restricted shares, which affected the total share capital of the company [2]. Group 2 - Heilongjiang Chuangda Group's shareholding decreased from 579,885,300 shares to 572,558,277 shares [1][2]. - The equity change occurred during the period of October 12, 2023, to December 8, 2023 [1]. - The company assures that the change in shareholding will not affect the status of the controlling shareholder or actual controller [2].